165 related articles for article (PubMed ID: 9297191)
1. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
[TBL] [Abstract][Full Text] [Related]
2. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
[TBL] [Abstract][Full Text] [Related]
3. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
[TBL] [Abstract][Full Text] [Related]
4. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
5. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
6. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
[TBL] [Abstract][Full Text] [Related]
7. [Acetylation phenotype in patients with lung cancer].
Cofta S; Lowicki Z; Młynarczyk W
Pneumonol Alergol Pol; 1995; 63(7-8):407-9. PubMed ID: 8520558
[TBL] [Abstract][Full Text] [Related]
8. [The pharmacokinetics of the marker preparations antipyrine and sulfadimezine in children suffering from bronchial asthma].
Ivan'ko OG; Muzylev VV
Farmakol Toksikol; 1991; 54(2):69-72. PubMed ID: 1884803
[TBL] [Abstract][Full Text] [Related]
9. Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
Singh SP; Pande JN; Khilnani GC; Kailash S
Indian J Chest Dis Allied Sci; 1996; 38(1):5-11. PubMed ID: 16892742
[TBL] [Abstract][Full Text] [Related]
10. [Acetylation phenotype in glomerulonephritis and its clinical significance].
Milejski P; Orzechowska-Juzwenko K; Strychowski J; Szewczyk Z; Klinger M
Pol Tyg Lek; 1987 May; 42(18):537-40. PubMed ID: 3628088
[No Abstract] [Full Text] [Related]
11. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
Ylitalo P; Auterinen L; Marttinen A; Koivula T
Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
[TBL] [Abstract][Full Text] [Related]
12. Drug metabolism in alcoholic liver disease.
Horváth T; Pár A; Past T; Tapsonyi Z; Ruzsa C; Kádas I; Jávor T
Acta Med Acad Sci Hung; 1982; 39(3-4):169-77. PubMed ID: 7185242
[No Abstract] [Full Text] [Related]
13. Acetylation phenotype in colorectal carcinoma.
Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
[TBL] [Abstract][Full Text] [Related]
14. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
Dubbels R; Kattner E; Sell-Maurer D; Schloot W
Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
[TBL] [Abstract][Full Text] [Related]
15. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
[TBL] [Abstract][Full Text] [Related]
16. Sulfadimidine kinetics in patients with various chronic liver diseases.
Horváth T; Past T; Par A; Kádas I; Jávor T
Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
[TBL] [Abstract][Full Text] [Related]
17. Antipyrine metabolism in lung cancer patients and their relatives.
Radzikowska E; Gazdzik W; Rowińska-Zakrzewska E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():297-308. PubMed ID: 9337547
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
[TBL] [Abstract][Full Text] [Related]
19. Sulphadimidine acetylation status in Gujarati and Marathi population.
Kshirsagar NA; Pohujani SM; Takle MR; Acharya VN; Satoskar RS
J Postgrad Med; 1987 Jul; 33(3):128-33. PubMed ID: 3430399
[No Abstract] [Full Text] [Related]
20. [Rapid and slow acetylation of sulfadimidine in patients with silicosis].
Hykes P; Elis J
Vnitr Lek; 1979 May; 25(5):463-6. PubMed ID: 452430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
